CJC-1295 + Ipamorelin research peptide vial, third-party tested

CJC-1295 + Ipamorelin

10mg / Vial
£40.00
£40.00
Skip to product information
CJC-1295 + Ipamorelin research peptide vial, third-party tested
  • CJC-1295 + Ipamorelin research peptide vial, third-party tested
  • CJC-1295 + Ipamorelin research peptide vial, third-party tested
CJC-1295 + Ipamorelin
Popular

CJC-1295 + Ipamorelin

£40.00
£40.00
Size
Type
For Research Purposes Only — Not For Human Use This product is intended solely for laboratory and in-vitro research. Not for human consumption, medical use, or self-administration.
Third-party tested
1–2 day tracked dispatch
Discreet packaging
99%+ purity guaranteed
For Research Use OnlyThis compound is strictly for laboratory and in-vitro research. Not for human consumption or medical use.
Reconstitution
Pen format? Pens are supplied pre-mixed and ready for research use — no reconstitution required. The steps below apply to lyophilized vials only.
  1. Swab both vial stoppers with alcohol and allow to dry.
  2. Draw the required volume of bacteriostatic water with a sterile syringe.
  3. Add the water slowly down the inside wall of the vial — never directly onto the powder.
  4. Swirl gently until fully dissolved. Never shake.
  5. Confirm the solution is clear and particle-free.
  6. Label with date and concentration, then refrigerate at 2–8 °C.
Full guide & dose calculator
Storage & Handling
  • Lyophilized vials: refrigerate sealed at 2–8 °C away from light; freeze at −20 °C for storage beyond 6 months.
  • After reconstitution: refrigerate at 2–8 °C; typically stable 4–8 weeks with bacteriostatic water. Do not freeze once mixed.
  • Pre-mixed pens: arrive ready to use — refrigerate at 2–8 °C with the cap on and never freeze.
  • General: avoid direct sunlight, heat and repeated temperature swings; minimise agitation.
Quality & Shipping FAQ
  • Is this compound tested? Yes — every batch is third-party tested by accredited labs (HPLC & mass spectrometry) at 99%+ verified purity.
  • How is it supplied? As lyophilized powder in a sealed sterile vial (or pre-mixed pen where offered), with research-use labelling.
  • How fast is dispatch? 1–2 working day dispatch, 2–3 days UK delivery, in plain discreet packaging.
  • What is it for? Strictly laboratory and in-vitro research — not for human or veterinary consumption, medical use or self-administration.
View the peer-reviewed research
Packaging update Our branded boxes are temporarily out of stock. Until new stock lands, orders ship in plain, discreet packaging — the same product inside, sealed and dispatched with the same care. Thank you for your patience.

CJC-1295 + Ipamorelin Blend

CJC-1295 and Ipamorelin are two peptides frequently studied together in growth-hormone secretagogue research. This blend combines them in a single research vial.

About the compounds

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), studied for its interaction with the GHRH receptor. Ipamorelin is a selective growth-hormone secretagogue studied for its interaction with the ghrelin / GH-secretagogue receptor. The two are researched together because they act on distinct, complementary pathways of the growth-hormone axis.

Specifications

  • Purity: 99%+ (third-party verified)
  • Independently tested before dispatch
  • Presented as lyophilised (freeze-dried) powder
  • Supplied for in-vitro laboratory research only

FAQ

Is it tested? Yes — every batch is independently tested to 99%+ purity before dispatch.
What form does it arrive in? Lyophilised powder.
What is this sold for? Laboratory and research use only. Not for human or animal consumption.

⚖ For Laboratory Research Use Only — Not for Human Consumption.
Peer-Reviewed Evidence

Research & Studies

Independent published research on CJC-1295 + Ipamorelin

CJC-1295 Growth Peptides Human Data

CJC-1295: Growth Hormone Releasing Hormone Analogue Research

Journal of Clinical Endocrinology & Metabolism · Teichman et al., 2006

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). Laboratory and controlled research studies have characterised its binding affinity to GHRH receptors and examined its pharmacokinetic profile in model systems, demonstrating sustained elevation of IGF-1 and growth hormone levels over 14 days — a dramatically extended duration compared to native GHRH.

GHRH Receptor IGF-1 Pharmacokinetics
CJC-1295 + Ipamorelin Growth Peptides Human Data

CJC-1295 + Ipamorelin: Complementary GH Secretagogue Pathways and Pulsatile Release Research

Journal of Clinical Endocrinology & Metabolism · Ionescu & Frohman, 2006

CJC-1295 and Ipamorelin represent two mechanistically distinct but complementary GH secretagogue pathways. CJC-1295 binds pituitary GHRH receptors to amplify GH pulse magnitude; Ipamorelin triggers GH release via the ghrelin receptor independently. Simultaneous activation of both pathways produces significantly greater physiologically natural GH output than either compound alone — the rationale underpinning their combination in research protocols.

GHRH Analogue GHS-R IGF-1
CJC-1295 Growth Peptides Human RCT

Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults

J. Clinical Endocrinology & Metabolism · Teichman et al., 2006

Randomised, placebo-controlled, double-blind ascending-dose trials of CJC-1295, a long-acting GHRH analogue, in healthy adults. Single subcutaneous doses raised mean plasma growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9–11 days; repeated dosing sustained IGF-I above baseline for up to 28 days. The compound was well tolerated at 30–60 µg/kg.

GHRH Analogue IGF-I Human RCT
Ipamorelin Growth Peptides Animal Model

Ipamorelin: Selective GHS-R Agonist Binding and Receptor Specificity Studies

European Journal of Endocrinology · Raun et al., 1998

Ipamorelin is a pentapeptide growth hormone secretagogue and selective agonist of the GHS-R. Research characterised its receptor binding specificity and selectivity profile compared to other GH secretagogues, demonstrating that unlike GHRP-6, Ipamorelin stimulates GH release without significantly elevating cortisol or prolactin — a key selectivity advantage making it valuable in research models requiring isolated GH secretagogue activity.

GHS-R Agonist Receptor Selectivity No Cortisol Spike
Ipamorelin Growth Peptides Animal Model

Ipamorelin, the First Selective Growth Hormone Secretagogue

European Journal of Endocrinology · Raun et al., 1998

The foundational pharmacology study characterising ipamorelin, a pentapeptide ghrelin-receptor agonist. Ipamorelin stimulated growth-hormone release with potency comparable to GHRP-6, but — uniquely among secretagogues of its era — did not raise ACTH or cortisol above GHRH-stimulated levels even at 200-fold the GH ED50, establishing its distinctive selective GH-releasing profile.

GH Secretagogue Ghrelin Receptor Selectivity
View the full research library →

You may also like